The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab results in ...
The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...
The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding ...
Findings showed concizumab-treated patients had an 86% reduction in annualized bleeding rate compared with no prophylaxis. The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci ...
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...
Findings from the Phase 3 study were presented at the 67 th American Society of Hematology Annual Meeting and Exposition and published in Blood The findings were shared today in an oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback